BioSpace News Archive

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical stage oncology and immunology focused biopharmaceutical company developing novel therapeutics for global markets, today reported financial results for the quarter ended 31 March 2019 and provided an update on its clinical activities.

Ophthalmic sensors and digital health company Implandata Ophthalmic Products GmbH (Implandata) announced today that it successfully attained CE mark for its EYEMATE system for use in patients undergoing keratoprosthesis surgery.

Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results from its landmark prospective, multi-center, pivotal clinical trial to validate the EyeArt® AI Eye Screening System for autonomous detection of diabetic retinopathy (DR), a blinding disease estimated to affect 191 million people globally by the year 2030

Santhera Pharmaceuticals (SIX: SANN) announces the Group’s audited financial results for 2018.

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the European Commission (EC) has granted conditional Marketing Authorization for Ondexxya™ (andexanet alfa)

Latest SAS® Platform release helps businesses and data scientists put analytics in action by automating complex tasks

Telligen has been selected to continue their work administering the SoonerCare Health Management Program by the Oklahoma Health Care Authority.

- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended March 31, 2019 and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs

Regeneron Pharmaceuticals, Inc. will webcast management presentations

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results for the first quarter ended March 31, 2019.